Wilmington, Delaware, 06 March 2025 (Globe Newswire) – Aimfinity Investment Corp. I (“Company” or “Aima”) (Nasdaq: Aimau), a special company for purchasing the special purpose involved as a 28-year-old, 2825, 2825 islands, in order to extend the date in which its complete full enterprise included from February 28, 202. deposited in its trust account (“Trust Account”) an aggregate of $ 55.823.8, or for $ 0.05 for class or ordinary shareholders held by public shareholders (“monthly extension payment”).
Pursuant to the fourth changed and reset company of the company and the association’s (“Current Card” articles), effectively January 9, 2025, the company may last on a monthly basis from January 28, 2025 to October 2025 or such a date that can be determined by its Board to complete a month of business. This is the second of the nine monthly stretches required under the current statute of the company.
About Aimfinity Investment Corp I
Aimfinity Investment Corp. I is an empty control company involved as a company excluded from the Kayman Islands in order to effect the merger, exchange of shares, purchase of assets, shares, reorganization or similar combination of business with one or more businesses or entities. The company has not chosen any objective of the business combination and there is no one on its behalf, has begun any essential, direct or indirect discussion, with any objective of the business combination regarding an initial combination of business with it. While the company will not be limited to a particular industry or geographical region in identifying and purchasing it a target company, it will not complete its initial combination of business with a target that is based in China (including Hong Kong and Macau) or performs a majority of its business in China (including Hong Kong and Macau).
Additional information and where to find
As discovered earlier, on October 13, 2023, the company entered into that designated agreement and the Union plan (as may be changed, supplemented or otherwise modified, “Union Agreement”), by and between the company, Docter Inc. Aimfinity Investment Merger Sub II, Inc., a delaware corporation and branches of full ownership of the buyer (“Merger Sub”), on the basis of which the company is proposing to enter a business combination with a document that includes a reassessment union and a purchase of purchase. This press release does not contain all the information that must be considered regarding the proposed business combination and is not intended to form the basis of any investment decision or any other decision on the business combination. Aima shareholders and other interested persons are advised to read, when available, the Declaration/Prospective of the Prosment and the changes in it and other documents submitted regarding the proposed business combination, as these materials will contain important information about AIMA, buyer or doctrine, and proposed business combination. When available, Proxi’s statement/prospectus and other important materials for the proposed business combination will be mail to AIMA shareholders from a record date to be created to vote in the proposed business combination. Such shareholders will also be able to obtain copies of the statement/prospectus of the representatives and other documents submitted to the Insurance and Exchange Commission (“SEC”), without payment, once available, on the SEC website at www.sec.govOr by running a request to Aima’s main office at 221 W 9TH St, PMB 235 Wilmington, Delaware 19801.
Future statements
This press release contains some “future statements” in the sense of the 1933 securities law and the act of exchange of securities of 1934, both changed. Statements that are not historical facts, including statements about the pending transactions described here, and the prospects and expectations of the parties are future statements. Such statements include, but are not limited to, statements regarding the proposed transaction, including the initial value of the enterprise and the after -closing capital, the benefits of the proposed transaction, the integration plans, the expected synergy and the possibilities of income, the foreseen financial and operating performance, including the estimates of the Company and the expected management. The words “wait”, “believe”, “evaluation”, “syno”, “plan” and similar expressions indicate future statements. These future statements are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions for general economic, market, industry and operational factors), known or unknown, which may make current results vary materially from indicated or anticipated.
Such hazards and uncertainties include, but are not limited to: (i) risks associated with the expected time and the likelihood of completing the pending business combination, including the risk that the transaction will not be closed due to one or more closing conditions for the transaction that is not satisfied or removed, such as non -approved approval, guarded, to preserve, respond, which are not accepted, for which they do not deal with approval, which are not, which do not deal, to,, of, such as, which do not deal with regulated approval, which are not, which are not, which are not obtained, which are not, such as, such as; are, dealing with approval, which are not accepted, which are not dealt with, which are not accepted, which are not, which are, indeed, of the transaction or required conditions, restrictions or restrictions on such approval; (ii) risks associated with Aima and Docter’s ability to successfully integrate businesses; (iii) the emergence of any event, change or other circumstances that may cause the conclusion of applicable transaction agreements; (iv) Risk that may have a negative material change regarding financial position, performance, operations or prospects of AIMA or Docter; (v) The risks associated with the breakdown of management time by ongoing business operations due to the proposed transaction; (vi) the risk that any notice of the proposed transaction may have detrimental effects on the price of the securities market of AIMA; (vii) The risk that the proposed transaction and its notice may have an adverse effect on the doctrine ability to maintain customers and to maintain and employ the main staff and maintain relationships with their suppliers and customers and their operating results and businesses in general; (VIII): Risks associated with the medical equipment industry, including but not limited to government regulatory changes and implementation, market competitions, competitive product and price activity; and (IX) Risks to the ability of the combined company to improve its products and services, execute its business strategy, expand its customers’ base, and maintain sustainable relationships with its business partners.
A further list and description of risks and uncertainties can be found in the prospectus presented on April 26, 2022 regarding AIMA’s initial public bid, AIMA annual report on the 10-K form for the fiscal year that ended on December 31, 2022, presented on April 17, 2023, and in the F-4/Proxy Proxy Form Declaration (File. 333-284658), presented from the first January from January, and in January, and in the first January of the form. 2025, as amended (“F-4”) regarding the proposed transactions and other documents that the parties may submit or supply with the SEC, which you encourage you to read. If one or more of these risks or uncertainties materialize, or they must be the basic assumptions to prove incorrect, the actual results may differ materially from those indicated or provided by such statements before. According to the circumstances, you are warned not to put unjust confidence in these future statements. Future statements relate only to the date they were made, and Aimfinity, Docter, and their subsidiaries do not undertake any obligation to update future statements to reflect events or circumstances after the date they were made, except as required by applicable law or regulation.
No bids or requests
This press release is not a statement of a representative or request of a proxy, consent or authorization regarding any securities or related to any possible transaction and does not constitute an offer to sell or a request of an offer to purchase any securities of AIMA, buyer or doctor, nor will there be any sale of such a state in such a state. The laws of securities of such a state or jurisdiction. No offers of securities will be made except by means of a prospectus that meets the requirements of the securities law.
Participants in request
Aima, Docter and their respective directors, executive officials, other management members and employees, according to SEC rules, may be considered to be participants in the request of AIMA shareholders regarding the proposed transaction. Information regarding persons who may, according to the SEC rules, be considered participants in the request of AIMA shareholders regarding the proposed business combination, is set out in F-4.
Contact information:
Corp Investment Aimfinity I
I-FA Chang
Chief executive
221 W 9TH ST, PMB 235
Wilmington, Delaware 19801